Basal Ganglia

Imaging AI Specialist Specialty-Focused AI

Neurosurgery Oncology Radiology

Oncology AI Surgical AI

Claim this company

Products

RT Elements (4.5)

Brainlab

Oncology AI

RT Elements (4.5) is a Brainlab AG software platform for AI-powered radiation therapy treatment planning, offering advanced tools for precise dose optimization and segmentation across various anatomical regions for oncology and radiosurgery.

See all 1 product →

About Basal Ganglia

It appears there is no healthcare AI company specifically named “Basal Ganglia.” The term “basal ganglia” refers to a group of structures deep in the brain that are primarily involved in controlling voluntary movements, but also play roles in decision-making, learning, and emotions.

The search results indicate that “basilar ganglia” was a misspelling of “basal ganglia” that appeared in a 2024 paper and blog post unveiling Google’s healthcare AI model, Med-Gemini. This error was later corrected in the blog post but not the original paper, raising concerns among critics about AI hallucination in healthcare. While the system did identify a missed pathology, it used an incorrect term to describe it. This incident highlights the critical need for accuracy and rigorous examination of AI models in healthcare to prevent potential misdiagnosis and harm to patients.

However, there are numerous AI companies working in neuroscience and brain-related healthcare, often focusing on areas that involve the functions of the basal ganglia, such as motor control, neurological disorders, and psychiatric conditions. For example, companies are developing AI to decode human brain activity for diagnosing neurological and psychiatric disorders, guide personalized treatment, and accelerate drug discovery. Some are also focusing on brain-computer interface (BCI) technology to revolutionize mental health treatments.

Focus Areas

Neuroscience Motor Control Learning Emotion Cognition

What Physicians Need to Know

Specialization

The company 'Basal Ganglia' appears to specialize in neurological research, particularly focusing on the basal ganglia structures of the brain and their role in motor control, learning, cognition, and emotion. They are involved in understanding and developing treatments for movement disorders like Parkinson's and Huntington's disease, as well as other neurological conditions such as Alzheimer's and various dementias.

Key Differentiators

Their key differentiators include a multi-pronged strategy for developing detailed computer models of the basal ganglia, starting with the striatum, and gradually expanding to incorporate other nuclei. They also focus on understanding how decisions are made when presented with conflicting actions and how correct decisions are learned and facilitated. The company also seems to be involved in developing non-dopaminergic therapies for conditions like Parkinson's disease, which could offer new treatment mechanisms.

Technology Stack

The company utilizes advanced computational modeling tools, including modified diffusion decision models (DDMs), in tandem with direct neural recordings from human basal ganglia areas. They also implement online use cases for single-cell building and validation of basal ganglia models, and work with single-cell models of striatal dSPN (MSN D1). Their approach incorporates spatial inhomogeneity based on gene expression data, likely from resources like the Allen Brain Atlas.

Physician Tip

For physicians, 'Basal Ganglia' offers insights into the complex functions of the basal ganglia in motor control, learning, and cognitive/emotional processing, which is crucial for diagnosing and treating related disorders. Their research into computational models and neural dynamics can provide a deeper understanding of decision-making processes and the underlying mechanisms of neurological conditions. The development of non-dopaminergic therapies, such as solengepras for Parkinson's disease, presents potential new treatment avenues, especially for patients who may not respond optimally to traditional dopaminergic approaches. Understanding the distinct computational roles of different basal ganglia components can aid in more targeted interventions and personalized medicine for movement disorders and other neurological dysfunctions.

While specific integration partners are not explicitly mentioned, the company's focus on computational modeling and data-driven approaches suggests potential integrations with neuroimaging platforms, electronic health records (EHR) for patient data analysis, and research databases for genetic and electrophysiological data. Collaboration with academic institutions and other biotech/pharmaceutical companies for clinical trials and drug development is also highly probable.

Products by Basal Ganglia

1 product in the directory

RT Elements (4.5)

Brainlab

Oncology AI

What the Web Says

The term "Basal Ganglia" primarily refers to a group of brain structures crucial for motor control, learning, and emotional processing, rather than a commercial company. While there isn't a company named "Basal Ganglia" with widespread product or employer reviews on platforms like G2, Glassdoor, or Capterra, the term appears in various contexts related to healthcare, research, and technology. For instance, it was mentioned in a 2024 Google healthcare AI model (Med-Gemini) that mistakenly used a similar, incorrect term, highlighting concerns about AI hallucination in healthcare. The basal ganglia are also a significant focus in neurological research, particularly concerning conditions like Parkinson's disease, stroke, and addiction. Some companies in the healthcare education and technology space, such as Intervoke and Pabau, offer products or services that involve detailed anatomical models or clinical documentation related to the basal ganglia.

Overall: Mixed

Strengths

Intervoke offers highly accurate 3D brain models, including detailed basal ganglia, beneficial for healthcare education.
Pabau provides structured digital forms for cognitive screening, useful for tracking outcomes in neurological conditions affecting the basal ganglia.
Research into the basal ganglia is advancing understanding and treatment for various neurological and psychiatric disorders.
The basal ganglia are integral to habit formation and procedural learning, which can be leveraged for productivity rituals.
Deep Brain Stimulation (DBS) targeting the basal ganglia is an established therapy for movement disorders and an emerging therapy for psychiatric conditions.
Understanding basal ganglia function is crucial for developing new neuromodulation strategies.

Limitations

Google's healthcare AI model (Med-Gemini) made a factual error related to the basal ganglia, raising concerns about AI hallucination in healthcare.
Damage to the basal ganglia can result in lifelong issues with movement, cognition, speech, muscle tone, and memory.
Dysfunction in the basal ganglia is associated with several movement disorders like Parkinson's disease and dystonia.
Drug and alcohol abuse directly affect the basal ganglia, blunting its sensitivity to dopamine and impacting the brain's reward system.
Some Reddit discussions highlight negative experiences with healthcare providers where basal ganglia-related conditions were mismanaged or led to further complications.
The detailed neuroanatomical organization of the basal ganglia has been subject to debate, leading to variability in terminology across studies.

Based on reviews from: Becker's Hospital Review, Reddit, Cleveland Clinic, WayUp, ScienceofPeople.com, Lifehacker, Official Teamly Blog, Pabau, Medbridge, AKUA MIND BODY, PMC, Abcam, Epilepsia, Frontiers, DocHub, ResearchGate, bioRxiv, Syracuse Medical Malpractice Lawyers DeFrancisco & Falgiatano, LLP, MDPI, Quora, Simply.Coach, Broward District Advisory Council

Last updated: 2026-10-16

Videos

News, demos, and interviews about Basal Ganglia.

Loading videos...

Videos load interactively. If none appear, search YouTube for Basal Ganglia →

View all on YouTube

Press & Coverage

Latus Bio

Latus Bio Announces New Data Presentation at American Society of Nephrology (ASN) Kidney Week 2026

Latus Bio announced new data presentation at American Society of Nephrology (ASN) Kidney Week 2026. The company is exploring gene therapy for basal ganglia diseases.

2026-10

NeurologyLive

Solengepras Meets Primary End Point in Phase 3 ARISE Trial of Parkinson Disease

Cerevance's solengepras, a non-dopaminergic therapy, met its primary endpoint in the Phase 3 ARISE trial for Parkinson's disease, aiming to restore balance in basal ganglia pathways.

2026-10

SciTechDaily

Researchers Map the Brain's Mysterious “Blue Place” and Discover a Record-Breaking Neuron - SciTechDaily

Researchers discovered the longest neuron ever measured in a mouse and found new clues about how the brain learns, drawing parallels between norepinephrine and dopamine systems in the basal ganglia.

2026-10

Seeking Alpha

BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews - Seeking Alpha

BridgeBio Pharma maintains a 'Strong Buy' rating with robust revenue growth and multiple late-stage pipeline catalysts, including treatments for conditions affecting the basal ganglia.

2026-10

NeurologyLive

Basal Ganglia Perivascular Space Burden Predicts Cognitive Decline

A study published in Neurology found that a higher burden of basal ganglia perivascular spaces independently predicts faster long-term decline in executive function and visuospatial skills among older adults.

2026-06

SV Health Investors

Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson's Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027 - SV Health Investors

Cerevance completed patient enrollment in its pivotal Phase 3 ARISE trial for Parkinson's disease and closed a $20 million Series C funding round, extending its operational runway into mid-2027.

2026-05

Futurism

Doctors Horrified After Google's Healthcare AI Makes Up a Body Part That Does Not Exist in Humans - Futurism

Google's healthcare AI, Med-Gemini, erroneously referred to a non-existent 'basilar ganglia' in a research paper, highlighting challenges with AI hallucinations in medical contexts.

2025-08

MeiraGTx

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

MeiraGTx reported progress in its late-stage clinical programs, including discussions with the FDA about using AI analysis of imaging data for AAV-GAD in Parkinson's disease.

2025-08

Frequently Asked Questions

What specific neurological conditions or disorders does Basal Ganglia's technology aim to address, particularly within motor control, learning, emotion, and cognition?

Basal Ganglia's technology focuses on a range of neurological conditions impacting motor control, learning, emotion, and cognition. Our solutions are designed to assist in the management and understanding of disorders such as Parkinson's disease, Huntington's disease, Tourette's syndrome, and certain forms of dystonia, by targeting the underlying basal ganglia dysfunction. We also explore applications in cognitive and emotional regulation deficits seen in conditions like OCD and depression, where basal ganglia circuits play a crucial role.

Can you provide an overview of Basal Ganglia's product pipeline and how these products integrate with existing clinical workflows for neurologists and neurosurgeons?

Basal Ganglia's product pipeline includes advanced neuroimaging analysis tools, neuromodulation devices, and AI-driven diagnostic support systems. Our products are developed to seamlessly integrate with existing clinical workflows by providing intuitive interfaces for data interpretation, offering compatibility with standard hospital IT systems, and delivering actionable insights that complement current diagnostic and therapeutic approaches. We prioritize interoperability to minimize disruption and maximize utility for healthcare professionals.

What evidence-based data or clinical trial results support the efficacy and safety of Basal Ganglia's products, and how do you ensure regulatory compliance?

Basal Ganglia is committed to rigorous scientific validation, with our products backed by extensive pre-clinical research and ongoing multi-center clinical trials. We adhere to the highest standards of regulatory compliance, holding certifications from major health authorities such as the FDA and EMA. Our data, including peer-reviewed publications and detailed trial reports, are readily available to demonstrate the efficacy and safety profiles of our technologies.

What is Basal Ganglia's pricing model for its products and services, and what kind of technical support and training do you offer to healthcare institutions?

Basal Ganglia offers flexible pricing models tailored to the specific needs and scale of healthcare institutions, including subscription-based access, per-procedure fees, and bundled solutions. We provide comprehensive technical support, including 24/7 remote assistance and on-site troubleshooting. Our training programs encompass in-depth product education, clinical application workshops, and ongoing professional development to ensure optimal utilization and proficiency for all users.

What strategic partnerships has Basal Ganglia established with academic institutions, research centers, or other industry leaders to advance neuroscience and clinical applications?

Basal Ganglia has forged strategic partnerships with leading academic institutions and prominent research centers globally, fostering collaborative research and development initiatives. These collaborations aim to accelerate the translation of cutting-edge neuroscience discoveries into practical clinical applications. We also engage with key industry leaders to integrate our technologies within broader healthcare ecosystems and enhance patient access to innovative solutions.

Given the rapid advancements in neuroscience, what is Basal Ganglia's long-term vision and strategy for maintaining company stability and product relevance in the evolving healthcare landscape?

Basal Ganglia's long-term vision is to remain at the forefront of neurological innovation through continuous investment in R&D, strategic intellectual property development, and agile product roadmapping. Our strategy for stability and relevance includes fostering a culture of innovation, actively monitoring emerging scientific trends, and building strong relationships with our clinical partners to ensure our solutions consistently address unmet needs in neuroscience and patient care.

Related Companies

Suggest an Edit → | Report an issue